Diagnostic tests and prognostic indicators

PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics. Sachpekidis C et al. Eur J Nucl Med Mol Imaging. 2014 Feb 22. [Epub ahead of print]. Inter-laboratory comparison of Beta-2 microglobulin and albumin methods: impact of assay variation on multiple myeloma staging. Fedele PL et al. Pathology. 2014…

Details

Emerging treatments

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Siegel DS et al. Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1. Daratumumab granted breakthrough drug status. Laubach JP et al. Expert Opin Investig Drugs. 2014 Feb 20. [Epub ahead of print]. Anti-CD40-mediated cancer immunotherapy: an update of recent and…

Details

Biology and Genetics

Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity. Tai YT et al. Blood. 2014 Feb 25. [Epub ahead of print]. Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma. Pappa CA et al. Tumour…

Details

Complications of myeloma and its treatments

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Palumbo A et al. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(13)70609-0. doi: 10.1016/S1470-2045(13)70609-0. [Epub ahead of print]. Lenalidomide and second malignancies in myeloma patients. Pratt G. Lancet Oncol. 2014 Feb 10. pii: S1470-2045(14)70001-4. doi: 10.1016/S1470-2045(14)70001-4. [Epub ahead of print].…

Details

General

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Palumbo A et al. J Clin Oncol. 2014 Jan 13. [Epub ahead of print]. Initial treatment of transplant-eligible patients in multiple myeloma. Rosiñol L et al. Expert Rev Hematol. 2014 Jan…

Details

Diagnostic tests and prognostic indicators

Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Corradini P et al. Methods Mol Biol. 2014;1109:209-37. doi: 10.1007/978-1-4614-9437-9_12. Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist. Nakamoto Y. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):10-1. doi: 10.1016/j.clml.2013.12.005. Epub 2013 Dec 21. Prognostic value of…

Details

Emerging treatments

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.Berenson JR et al. Leukemia. 2014 Jan 16. doi: 10.1038/leu.2014.27. [Epub ahead of print].Immunotherapy for multiple myeloma.Rosenblatt J et al. Expert Rev Hematol. 2014 Jan 13. [Epub ahead of print].Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin…

Details

Related conditions

Autologous Stem Cell Transplantation for POEMS Syndrome. Nakaseko C.Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):21-3. doi: 10.1016/j.clml.2013.12.009. Epub 2013 Dec 22. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Patel K et al. Bone Marrow Transplant. 2014 Jan 13. doi: 10.1038/bmt.2013.209. [Epub ahead of print]. Can autologous bone marrow transplantation improve systolic function…

Details